Cushing's syndrome in prostate cancer

Urologia Internationalis

Volumn 63, Issue 2, 1999, Pages 126-129

  Haukaas, Svein Andreas ^a   Halvorsen, Ole Johan ^a   Nygaard, Svein Jacob Tjoflaat ^a   Paus, Elisabeth ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cushing's syndrome; Prostate cancer; Small cell carcinoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; ESTROGEN; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CUSHING SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SEPTICEMIA; SMALL CELL CARCINOMA;

EID: 0032698146     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030431     Document Type: Article

References (16)

1. Meador CK, Liddle GW, Island DP, Nicholson WE, Lucas CP, Nuckton JG, Luetscher JA: Cushing's syndrome in patients with tumors arising from 'nonendocrine' tissue. J Clin Endocrinol Metab 1962;22:693-703.
2. Vuitch MF, Mendelsohn G: Relationship of ectopic ACTH production to tumor differentiation: A morphologic and imiminhistochemical study of prostatic carcinoma with Cushing's syndrome. Cancer 1981;47:296-299.
3. Ball SG, Davison JM, Burt AD, McNicol AM, Baylis PH: Cushing's syndrome secondary to ectopic ACTH secretion from a primary ovarian carcinoma. Clin Endocrinol 1996;45:775-778.
4. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-268.
5. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma: Recent findings and new concepts. Cancer 1995;75:1850-1859.
6. Paus E, Nustad K: Immunoradiometric assay for alpha gamma- and gamma gamma-enolasc(neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles. Clin Chem 1989;35:2034-2038.
7. Paus E, Nilsson O, Bønner OP, Fosså SD, Otnes B, Skovlund E: Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia J Urol 1998;159:1599-1605.
8. Børmer OP, Nustad K: Selection of monoclonal antibodies for use in an immunometric assay of carcinoembryonic antigen. J Immunol Methods 1990;127:171-178
9. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG: Small cell carcinoma of the prostate. I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.
10. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablative therapy as studied in the Dunning R-3327 adenocarcinoma. Cancer Res 1981;41:5070-5075.
11. Abrahamsson PA, Falkmer S, Fält K, Grimelius L: The course of neuroendocrine differentiation in prostatic carcinomas: An immunohistochemical study testing chromogranin A as an 'endocrine marker'. Pathol Res Pract 1989; 185:373-380.
12. Frkovic-Grazio S, Kraljic I, Trnski D. Tarle M: Imniunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor. Anticancer Res 1994;14:2151-2156.
13. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993; 71:3952-3965.
14. Deftos LJ, Nakada S, Burton DW, di Sant' Agnese PA, Cockett ATK, Abrahamsson PA: Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
15. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølncrød OK, Waldum HL: Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
16. Galanis E, Frytak S, Lloyd RV: Extrapulmonary small cell carcinoma. Cancer 1997;79: 1729-1736.